Hepatology practice marketing: liver care wording

A liver clinic has an unusual marketing position. For one of its main conditions, hepatitis C, federal health agencies say antiviral medicines can cure it, so the honest message is a hopeful one. For another, fatty liver disease, the federal pages describe weight loss and managing related conditions as the core of care. Around both sits a large market of liver cleanses, detox teas and supplements that promise far more than the evidence shows. And the people a hepatology practice wants to reach may carry stigma about how they were infected or about their drinking. Good marketing for a liver clinic states the cure exactly as federal sources state it, keeps detox claims off the site, and writes for readers who may be reluctant to ask for help.

Two related topics have their own guides and are not repeated here. Digestive care, colorectal screening pages and recall messages are covered in our gastroenterology practice marketing guide. Alcohol and drug treatment programs, including ad certification and confidentiality of treatment records, are covered in our addiction treatment marketing guide. This guide covers what is specific to the liver clinic.

This is general information, not legal or medical advice. Scope of practice and licensing rules are set state by state. Sources cited were checked on October 30, 2026: the NIDDK pages Hepatitis C (last reviewed December 2024), Treatment for NAFLD and NASH (last reviewed April 2021) and Cirrhosis (last reviewed June 2023), the MedlinePlus health topic pages Hepatitis C (last updated May 31, 2024) and Steatotic Liver Disease (last updated July 10, 2026), the CDC pages Clinical Screening and Diagnosis for Hepatitis C, Hepatitis C Basics and Clinical Testing and Diagnosis for Hepatitis B, the NCCIH page Hepatitis C and Dietary Supplements (last updated May 2018), 42 CFR 2.11 and 2.12, 15 U.S.C. 45 and 52, the FTC Health Products Compliance Guidance, 16 CFR 255.2, 45 CFR 164.508 and the Google Ads healthcare and restricted targeting policies.

State the hepatitis C cure the way federal sources state it

The National Institute of Diabetes and Digestive and Kidney Diseases page on hepatitis C says doctors treat hepatitis C with antiviral medicines that attack the virus, that medicines can cure the large majority of cases, and that treatment lasts 8 to 12 weeks for chronic hepatitis C, though some people need to take the medicines for longer. It also says early diagnosis and treatment can prevent liver damage, that people with chronic hepatitis C may have few or no symptoms until complications such as cirrhosis develop, and that a person who had hepatitis C in the past can get it again. The MedlinePlus page on hepatitis C says the antiviral medicines can cure the disease in the large majority of cases, and that there is no vaccine for hepatitis C.

That is a strong, true message, and a practice can use it. The care is in the wording. A page can say that federal health agencies describe hepatitis C as curable with antiviral medicines for the large majority of people, link to NIDDK, and explain what treatment involves. What it should not do is turn that population statement into a promise to the reader.

Phrases that need rewriting:

“We cure hepatitis C” or “certain cure” as a promise to each patient. Write “Antiviral medicines can cure hepatitis C in the large majority of people, according to NIDDK. We will test, explain your results and talk through treatment with you.”
“Cured for life” or “you will never get it again”. NIDDK and CDC both say a person who was cured can be infected again.
“No side effects”. NIDDK tells patients to talk with their doctor about the possible side effects of treatment.
A cure rate for your own clinic that you cannot trace to your own documented and reviewed data. If you cite the federal figure, attribute it to NIDDK and link the page.
“Repairs your liver” or “reverses cirrhosis” for antiviral treatment. NIDDK says that if hepatitis C leads to cirrhosis, patients should see a doctor with experience treating liver diseases, and describes treating the complications of cirrhosis, not undoing it.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices or services. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence. Quoting a federal source accurately meets that bar; stretching it into a personal promise does not.

Screening pages that follow the CDC recommendation

Testing is where a liver clinic can reach people who do not know they are infected. The CDC page Clinical Screening and Diagnosis for Hepatitis C says CDC recommends hepatitis C screening at least once in a lifetime for all adults 18 and older, and for all pregnant women during each pregnancy, except in settings where prevalence is very low. It recommends one-time testing for people with recognized risk factors or exposures, and routine periodic testing for people with ongoing risk factors. It also says clinicians should test anyone who requests a hepatitis C test, regardless of stated risk factors, because patients may be hesitant to share stigmatizing risks.

For hepatitis B, the CDC page Clinical Testing and Diagnosis for Hepatitis B says CDC recommends screening all adults 18 and older for hepatitis B at least once in their lifetime using a triple panel test, and describes this as a simpler and less stigmatizing strategy than the earlier risk-based recommendations.

A screening page built on these recommendations does not need to ask readers to admit to anything. It can say that CDC recommends a one-time hepatitis C test and a one-time hepatitis B test for all adults, that anyone who asks can be tested, and how to book. That framing is accurate and it removes the barrier the CDC page itself names. Leave the risk factor list for the clinician conversation or for a linked CDC page, rather than making it the headline.

Fatty liver pages: describe care, not a quick fix

Fatty liver disease is a condition readers arrive with after an ultrasound or a lab result. The MedlinePlus page Steatotic Liver Disease explains the current names: metabolic dysfunction-associated steatotic liver disease, or MASLD, which used to be called nonalcoholic fatty liver disease, and alcohol-associated liver disease. It says both have few or no symptoms in a large share of people, that the first step in treating MASLD is weight loss, and that people should not stop taking any medicines unless their provider tells them to.

The NIDDK page Treatment for NAFLD and NASH says losing weight through healthy food choices, smaller portions and physical activity can improve the condition, that physical activity alone is beneficial, and that doctors recommend losing weight gradually because rapid weight loss and malnutrition can make liver disease worse. The page was last reviewed in April 2021, and medicine options for this condition have been changing, so a practice page should not repeat any statement about which medicines are or are not approved without checking the current FDA record. The safer path is to say that medicine decisions are made with the prescriber and to keep drug names out of marketing copy.

Fatty liver pages that hold up:

Use both the current and former names, since readers search for both, and link to MedlinePlus for the definitions.
Describe the clinic’s process: tests to measure liver fat and scarring, review of medicines and alcohol use, and a plan for weight, diabetes, blood pressure and cholesterol.
Do not promise a reversal, a timeline or a target result. Describe what the federal pages say can improve, and that results depend on the person.
Do not market rapid weight loss for fatty liver. NIDDK says rapid weight loss can make liver disease worse.
If the clinic offers a weight management program, link it and follow the rules in our weight loss guide rather than repeating them on the liver page.

Our weight loss clinic marketing guide covers program claims, before and after photos and medication ads.

Detox, cleanse and supplement claims

Liver cleanse and detox products are among the claims a liver clinic should keep furthest from its site. A practice that sells or recommends a detox kit, a cleanse protocol or a liver support supplement takes on the FTC evidence standard for every claim it makes about that product. Federal sources do not support those claims and give a caution instead. The NIDDK treatment page tells readers to talk with their doctor before using dietary supplements or complementary practices, and says some herbal remedies can actually damage the liver. MedlinePlus repeats that some supplements or herbal remedies can damage the liver.

For hepatitis C specifically, the NCCIH page Hepatitis C and Dietary Supplements says several studies of silymarin, the milk thistle extract, in people with hepatitis C did not find beneficial effects, that one trial found higher than standard doses were no better than placebo, and that research has not produced clear evidence that probiotics help. A liver clinic that sells such a product with a liver claim is making a claim its own field’s federal sources do not support.

Wording that holds up is a caution, not a sale: “Tell us about every supplement, herb and over-the-counter medicine you take. Some can harm the liver, and we will review them with you.” That is consistent with NIDDK and MedlinePlus, and it is a useful service. Our guide to selling supplements in a medical practice covers the wider rules.

Write about alcohol and drug use without stigma

Liver disease and substance use are linked, and the copy needs to handle that with care. MedlinePlus says stopping alcohol is the central part of treating alcohol-associated liver disease, and that people who need help may benefit from counseling, a recovery program, or medicines. The CDC hepatitis C screening page names injection drug use and shared equipment among the risks for which testing is recommended. A liver clinic will see patients for whom both are part of the story.

Practical ways to write for them:

Use person-first wording: a person who drinks heavily or a person who injects drugs, not a label.
Use the current condition names. MedlinePlus says alcohol-associated liver disease used to be called alcoholic fatty liver disease.
Say plainly that the clinic will ask about alcohol and drug use because it affects liver care, and that the question is about treatment, not judgment.
Offer the route to help: name the clinic’s own support or its referral process for counseling and recovery programs, without promising a result.
Keep fear-based copy off condition pages. A reader who already feels ashamed is less likely to book after being told what will happen if they do not.

If the clinic itself provides alcohol or drug use disorder treatment, an extra set of confidentiality rules may apply. Under 42 CFR 2.11, a program includes a person or an identified unit that holds itself out as providing, and provides, substance use disorder diagnosis, treatment or referral for treatment, and 42 CFR 2.12 applies the rules to federally assisted programs. Whether a liver clinic is a Part 2 program is a question for counsel. Our addiction treatment marketing guide covers what it means for marketing.

Patient stories, tracking and ads

A story from a patient who was tested, treated and cured of hepatitis C can be persuasive. Under 16 CFR 255.2, an advertisement that uses a consumer endorsement about a key attribute of a service is likely to be read as representing that the endorser’s experience is representative, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. Under 45 CFR 164.508, a covered entity needs a valid written authorization from the patient before using their health information for marketing. Hepatitis and alcohol history are details people protect closely, so let the patient choose what is shared, review the final words and decide whether their name or photo appears.

Liver risk quizzes, symptom checkers and booking forms collect health information. Keep that data out of advertising and analytics tools unless you have checked what each tool receives and what your agreements with it cover, as our guide to tracking pixels on practice websites explains.

For ads, the Google Ads healthcare and medicines policy says Google restricts the use of prescription drug terms in ads, landing pages and keywords, so naming antiviral medicines in a campaign may be limited or not allowed depending on the location. The restricted targeting policy for personalized advertising lists health among its sensitive interest categories, so audiences cannot be built around a person’s liver condition or hepatitis status. Keyword and location targeting with an honest landing page is the safer route, and our healthcare ad policy basics guide covers the wider policy.

Illustration: two ads for the same clinic

Illustration: an ad reads “Hepatitis C cured for life, every time. No side effects. Plus our 7-day liver detox to repair the damage.” It promises each reader a cure, ignores that NIDDK and CDC say reinfection can happen, dismisses side effects NIDDK tells patients to discuss, and sells a detox product with a repair claim that federal sources do not support.

Illustration: a second ad for the same clinic reads “Hepatitis C can be cured with antiviral medicines for the large majority of people, according to NIH. Testing and treatment at [Practice name] with a [license type]. CDC recommends one test for every adult.” The landing page links to NIDDK and CDC, explains testing and treatment, asks every patient about supplements, and does not ask readers to disclose risk factors before booking.

Checklist before a liver clinic campaign goes live

Hepatitis C cure wording is attributed to NIDDK, CDC or MedlinePlus and is not stated as a promise to the reader.
No page says cured for life, no side effects, reverses cirrhosis or repairs the liver.
Screening pages follow the CDC recommendation for all adults and say that anyone who asks can be tested.
Fatty liver pages use both current and former names, describe the care process and do not market rapid weight loss.
No statement about which medicines are approved appears without a current FDA check, and drug names stay out of ads.
No detox, cleanse or liver support product is sold or recommended with a liver claim; supplement pages carry the NIDDK caution.
Copy about alcohol and drug use is person-first and points to help, and counsel has reviewed whether 42 CFR Part 2 applies.
Quizzes and forms do not send health details to ad or analytics tools.
Each patient story has a signed authorization, the patient chose what is shared, and the page says results vary.
Ads do not target by health condition, and each clinician is shown with their license type and exact title.

Clinics that run testing days, rapid tests and recall messages to find people who have not been tested can follow our guide to hepatitis C testing and treatment outreach, which covers screening pages, same-visit testing, outreach texts and referrals from substance use programs.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For a liver clinic, that means condition and screening pages written in plain, stigma-aware words with links to federal sources, ads that state the hepatitis C cure accurately, and booking and inquiry forms that keep health details away from tracking tools. We do not decide clinical content, treatment choices or whether confidentiality rules for substance use treatment apply; your medical director, your counsel and your state’s rules do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Can a liver clinic say it cures hepatitis C?

NIDDK and MedlinePlus say antiviral medicines can cure hepatitis C in the large majority of cases. A clinic can say that, attributed to the source, and explain its treatment process. It should not promise each reader a cure or say a cure lasts for life, since NIDDK and CDC say reinfection can happen.

Who should a hepatitis C screening page speak to?

CDC recommends hepatitis C screening at least once for all adults 18 and older and for pregnant women during each pregnancy, and says clinicians should test anyone who asks. A page can speak to every adult without asking readers to disclose risk factors.

Can we promote a liver detox or cleanse?

A detox or cleanse claim needs competent and reliable scientific evidence under the FTC standard. NIDDK and MedlinePlus caution that some herbal remedies and supplements can damage the liver, and NCCIH reports that studies of milk thistle in hepatitis C did not find benefits.

What should fatty liver pages say about treatment?

MedlinePlus says the first step in treating MASLD is weight loss, and NIDDK says gradual weight loss and physical activity can improve the condition while rapid weight loss can make it worse. Describe the care process and leave medicine choices to the prescriber.

Does 42 CFR Part 2 apply to a liver clinic?

It can apply to a federally assisted program that holds itself out as providing, and provides, substance use disorder diagnosis, treatment or referral for treatment. Whether a particular clinic is covered is a question for counsel.

Can we run Google Ads to people with hepatitis or fatty liver?

Google’s restricted targeting policy lists health among its sensitive categories, so you cannot build audiences around a liver condition, and its healthcare policy restricts prescription drug terms. Use keyword and location targeting with an honest landing page.

Hepatology practice marketing: hepatitis C cure wording, fatty liver, detox claims and stigma